



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/914,795

09/05/2001

Gunther Berndt

49727

4232

26474

7590

05/24/2006

NOVAK DRUCE DELUCA & QUIGG, LLP
1300 EYE STREET NW
SUITE 400 EAST TOWER
WASHINGTON, DC 20005

EXAMINER

GOLLAMUDI, SHARMILA S

ART UNIT

PAPER NUMBER

1616

DATE MAILED: 05/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/914,795	Applicant(s) BERNDL ET AL.	
	Examiner Sharmila S. Gollamudi	Art Unit 1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 February 2006.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Request for Continued Examination filed 2/15/06 is acknowledged. Claims 1-8 are pending in this application.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/15/06 has been entered.

Response to Arguments

Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-8 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term "accelerated release" in claim 1 is a relative term, which renders the claim indefinite; i.e. accelerated as compared to? The term "accelerated" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.

Art Unit: 1616

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by EP 0564945.

EP discloses a method of controlling insects. Example 3 discloses a process wherein 20 parts cyfluthrin, 0.1 parts triadminenol, 80 parts beta-cyclodextrin, and 50 parts Carbowax 20M (PEG with a molecular weight of 20,000, and 150 parts of a polymer carrier material is extruded using a twin screw extruder at a temperature of 160 degrees Celsius. Note that “suitable for oral or rectal administration to humans and animals” is intended use that is not given patentable weight.

With regard to claim 7, it is the examiner’s position that EP would have the same functional property since the devices are substantially similar and thus the properties must be the same. See MPEP2112 IV, V and 2112.01.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1616

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baert et al (6,365,188) in view of Goertz et al (4,801,460).

Baert et al teach a solid mixture of cyclodextrin prepared via melt extrusion. The melt-extrusion mixture contains cyclodextrin and an active agent. See column 3, lines 26-40. Baert discloses that cyclodextrins increase the solubility of the insoluble drugs such as anti-fungals. Any suitable compound may be utilized provided that the drug does not decompose at high temperatures. See column 2, lines 45-60. Baert teaches melt-extrusion as the polymer extrusion technique wherein an active agent is embedded in one or more carriers. In this technique the active and excipients are molten in the extruder and hence embedded in the thermoplastic and thermomelting polymers. See column 3, lines 26-40. Additionally, the mixture may contain additives such as instant polyethylene glycol. See column 4, lines 34-42. The process includes a) mixing the cyclodextrin with the active agent and additives, b) heating the mixture until melting of one of the components occurs, c) forcing the mixture through one or more nozzles, and d) cooling the mixture to obtain a solid product. See column 4, lines 15-25. Although, a temperature of 239 degrees Celsius is exemplified, Baert discloses that different temperatures may be applied and discloses the method of ascertaining the required temperature. See column 5, lines 1-12. The

Art Unit: 1616

extruder has counterrotating screw with different shapes. See column 5. The melt-extruded mixture is preferably prepared without water or a solvent. The preferred ratio of the active to cyclodextrin is 1:3. See column 7, lines 64 to column 8, lines 4 and examples.

Baert et al do not teach the instant polymer binder in the extrusion mixture or the molecular weight of the PEG. Additionally, Baert does not teach the instant temperature of 170 degrees Celsius.

Goertz teaches preparation of solid pharmaceutical forms. Goertz teaches providing solid pharmaceutical forms by mixing one or more pharmaceutical agents with one or more fusible, pharmacological binders, and extruded into a shaped form. The binder must soften or melt at 50 to 180 degrees Celsius and preferably 60-160 degrees Celsius. See 2, lines 25-30. The fusible binder may be NVP and vinyl acetate copolymer. See column 3, lines 10-20. The binder is utilized in an amount of not less than 50% and preferably not less than 70%. See column 4, line 45-55. The tablets completely dissolve in 30 minutes. See column 7.

It would have been obvious at the time the invention was made to combine the teachings of Baert et al and Goertz et al and utilize the instant NVP and vinyl acetate copolymer in the extrusion mixture of Baert et al. One would have been motivated to do so since both Baert teaches melt-extrusion is the technique wherein an active agent is embedded in *one or more* carriers (thermoplastic polymers) wherein cyclodextrin acts as the carrier in Baert's formulation. However, it would have been obvious to add another carrier since as taught by Baert and Goertz, melt- extrusion allows for one or more carriers in the composition. A skilled artisan would have expected similar results since both references are directed to the melt extrusion process. Further, the if the instant polymeric carrier is added to the composition, the instant temperature would be

Art Unit: 1616

utilized in the process since as taught by Baert, only one of the components need to melt to dissolve the rest of the components. With regard to claim 7, the instant functional limitation will naturally flow from the instant combination.

Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baert et al (6,365,188) in view of Stella et al (6,046,177).

Baert et al teach a solid mixture of cyclodextrin prepared via melt extrusion. The melt-extrusion mixture contains cyclodextrin and an active agent. See column 3, lines 26-40. Baert discloses that cyclodextrins increase the solubility of the insoluble drugs such as anti-fungals. Any suitable compound may be utilized provided that the drug does not decompose at high temperatures. See column 2, lines 45-60. Baert teaches melt-extrusion as the polymer extrusion technique wherein an active agent is embedded in one or more carriers. In this technique the active and excipients are molten in the extruder and hence embedded in the thermoplastic and thermomelting polymers. See column 3, lines 26-40. Additionally, the mixture may contain additives such as instant polyethylene glycol. See column 4, lines 34-42. The process includes a) mixing the cyclodextrin with the active agent and additives, b) heating the mixture until melting of one of the components occurs, c) forcing the mixture through one or more nozzles, and d) cooling the mixture to obtain a solid product. See column 4, lines 15-25. Although, a temperature of 239 degrees Celsius is exemplified, Baert discloses that different temperatures may be applied and discloses the method of ascertaining the required temperature. See column 5, lines 1-12. The extruder has counterrotating screw with different shapes. See column 5. The melt-extruded mixture is preferably prepared without water or a solvent. The preferred ratio of the active to cyclodextrin is 1:3. See column 7, lines 64 to column 8, lines 4 and examples.

Art Unit: 1616

Baert et al do not teach the instant polymer binder in the extrusion mixture or the molecular weight of the PEG. Additionally, Baert does not teach the instant temperature of 220 degrees Celsius.

Stella et al teaches controlled release forms of solid formulations containing sulfoalkyl ether cyclodextrin (SAE-CD). The controlled release formulation contains a core containing an active agent, at least on SAE-CD, at least one rate controlling modifier, and at least one pharmaceutical acceptable excipient. See column 6, lines 1-7. The core may be made by several methods including melt extrusion. Note example 10. The release rate modifier provides either a rapid, delayed, sustained, timed, or targeted release of the active agent. See column 27, lines 40-50. Stella teaches varying the ratio of the rate controlling modifier and the drug such as 10:1 and 5:1, determines the release rate. The rate control modifier (exemplified HPMC) is varied from 25% to 50%. See column 17. Further, Stella teaches the use of binders such as celluloses, polyethylene glycols, polyvinylpyrrolidone, vinyl alcohol polymers, in order to obtain suitable products and Stella teaches the binders melt at 150 degrees Celsius. See column 27, lines 5-30. Some of the binders named also function as the release rate modifier. See column 27, lines 48-50. The binder is utilized in different proportions in different examples. Example 10 discloses a process utilizing melt extrusion wherein 2.5% of an active, 67.5% of SAE-CD, 10.5% PEG 6000, and excipients are melted at 60 degrees Celsius to form granules. Lastly, Stella et al disclose that major portion (lower limit 50% and preferably greater than 95%) of the SAE-CD is not complexed to the active agent (col. 12, lines 9-22).

It would have been obvious at the time the invention was made to combine the teachings of Baert et al, Stella et al, and Murata et al and utilize the instant water-soluble polymer PEG in

Art Unit: 1616

the extrusion mixture of Baert et al. Firstly, one would have been motivated to do so since Stella teaches the use polymer binders such as PEG provide suitable products. Further, although Stella exemplifies the use of 10.5% PEG, it would have been obvious to manipulate the concentration during routine optimization and experimentation absent a showing of the unexpectedness of the instant concentration. With regard to claim 7, the instant functional limitation will naturally flow from the instant combination.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharmila S. Gollamudi whose telephone number is 571-272-0614. The examiner can normally be reached on M-F (8:00-5:30), alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on 571-272-0887. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sharmila S. Gollamudi
Examiner
Art Unit 1616

